Browsing Tag

NASH Cirrhosis

UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021,…

Jason Junior Nov 7, 2021

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic insufficiencyInnovating in Liver Cirrhosis: Belapectin’s NAVIGATE phase 2b/3 study…

Health

Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E.…

Jason Junior Sep 21, 2021

NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt…